Almirall stock analysis
Almirall (0O9B) Share Price & Analysis
0O9B Stock Chart & Stats
- Day’s Range
- EUR 10.76 - EUR 10.98
- 52-Week Range
- EUR 9.88 - EUR 13.98
- Previous Close
- EUR 10.74
- Volume
- N/A
- Average Volume (3M)
- 5,443
- Market Cap
- EUR 2.35B
- Enterprise Value
- EUR 2.41B
- Total Cash (Recent Filing)
- EUR 355.41M
- Total Debt (Recent Filing)
- EUR 363.67M
- Price to Earnings (P/E)
- 32.1
- Beta
- 0.90
- Next Earnings
- Feb 22, 2027 (Est.)
- EPS Estimate
- 0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.71%
Bulls Say, Bears Say
Bulls Say
Improved Revenue And Profitability
The sharp TTM revenue acceleration alongside positive profitability indicates stronger commercial performance across Almirall’s branded pharmaceutical portfolio. If sustained, improved scale and healthy gross margins can support reinvestment in dermatology products, geographic reach, and lifecycle management.
Conservative And Improving Leverage
Declining leverage and expanding equity provide Almirall with greater financial resilience than its earlier position. A conservative balance sheet can reduce financing pressure, preserve flexibility for product development or partnerships, and help the company absorb fluctuations in pharmaceutical earnings.
Stronger Cash Generation
Strong TTM operating and free cash flow improves Almirall’s ability to fund research, commercialization, licensing activity, and shareholder commitments internally. Robust cash generation also provides a buffer against volatility and reduces reliance on additional borrowing to support growth.
Bears Say
Historical Earnings Volatility
The return to profitability is encouraging, but the multi-year swings in net results make current earnings power less predictable. Continued volatility could complicate planning, reduce confidence in margin durability, and limit the consistency of funds available for investment in the product portfolio.
Inconsistent Cash Flow Quality
Recent cash improvement has not yet established a consistently reliable pattern across the reported history. Earlier negative or breakeven free cash flow suggests that operating performance may not always translate into deployable cash, potentially constraining investment and capital allocation during weaker periods.
Returns Not Fully Normalized
Almirall’s improved profitability has not yet produced strong returns relative to its growing equity base. Persistently modest capital returns would indicate that resources are not being converted into earnings efficiently, limiting the long-term compounding potential of the business despite balance-sheet stability.
Almirall News
0O9B FAQ
What was Almirall’s price range in the past 12 months?
What is Almirall’s market cap?
When is Almirall’s upcoming earnings report date?
How were Almirall’s earnings last quarter?
Is Almirall overvalued?
Does Almirall pay dividends?
What is Almirall’s EPS estimate?
How many shares outstanding does Almirall have?
What happened to Almirall’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Almirall?
What is the TipRanks Smart Score and how is it calculated?
Almirall Stock Smart Score
Company Description
Almirall
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Carlos Gallardo Piqué
- Employees
- 2,097
- Website
- www.almirall.com
- Address
- Ronda Del General Miter, 151, Barcelona, CT, 08022, ES
Almirall (0O9B) Earnings & Revenues
0O9B Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 9 | 0 | 3 |
